According to our LinkedIn poll last month, a large percentage of respondents had a personal connection to Alzheimer's Disease Psychosis. While there are no FDA-approved medications for these symptoms, MapLight is working to develop potential new treatment options. Learn more about MapLight's focus on Alzheimer's. https://lnkd.in/d5wESj-M
MapLight Therapeutics, Inc.
Biotechnology Research
Palo Alto, CA 8,417 followers
Creating breakthrough innovative therapeutics for serious CNS disorders
About us
Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
- Website
-
http://maplightrx.com
External link for MapLight Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Palo Alto, CA
- Type
- Privately Held
Locations
-
Primary
Palo Alto, CA, US
-
Boston, Massachusetts, US
Employees at MapLight Therapeutics, Inc.
Updates
-
The MapLight Therapeutics, Inc. team had a great time at the Alzheimer's Association®’s International Conference (AAIC) in Philadelphia. We are energized by the passion of the Alzheimer’s research community to discover new therapeutic options for patients. We presented a scientific poster for our ML-007 program (M1/M4 muscarinic agonist), which demonstrated pro-cognitive potential in preclinical models of cognitive impairment and psychosis. It was encouraging to see the excitement around investigational muscarinic therapies and their potential in the treatment of Alzheimer’s disease psychosis. You can learn more about our ongoing research by visiting our website. https://lnkd.in/gWZG5wsj #AlzheimersAssociation #EndAlz #Neuroscience
-
-
Today is the last day of the Alzheimer's Association®’s International Conference® (AAIC) – and we're pleased to take part in "AAIC For All" to cap off our time in Philadelphia. This event is a new extension of AAIC, and serves as an opportunity for clinicians and interested community members to learn about the latest Alzheimer's disease research findings. "AAIC For All" kicks off in an hour (at 9am ET), but it's not too late to register. By registering, you will get online access to the content for 30 days, which is great for those that may not be able to tune in live. Register here. https://lnkd.in/dNbjB7Jq Learn more about AAIC For All here. https://lnkd.in/eR4VDuai
-
Our discovery platform holds the potential to fill a void by identifying neural circuits causally linked to disease and targeting them for therapeutic modulation. Utilizing this approach, we are advancing a robust pipeline of product candidates for some of the most challenging central nervous system conditions such as schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder. https://lnkd.in/gudWcFta
-
-
It's Throwback Thursday – and we're throwing it back to June with a snapshot of our recent offsite! Our team had a fantastic time connecting and collaborating. At MapLight Therapeutics, Inc., we value a strong and supportive culture that fosters innovation and teamwork. www.maplightrx.com
-
-
MapLight Therapeutics, Inc. is excited for our upcoming poster presentation at the Alzheimer's Association® International Conference (AAIC) in Philadelphia! Join us on Monday, July 29th, from 3:30 to 4:15 PM (poster 43) to learn more about ML-007's effects in preclinical models of psychosis and cognitive impairment. Looking forward to seeing you there! #AAIC24 #AlzheimersResearch #CognitiveImpairment #PosterPresentation
-
On World Brain Day, we emphasize the importance of brain health and the ongoing fight to support those living with CNS disorders. At MapLight Therapeutics, Inc., we are dedicated to advancing research and developing potential new treatments to support better brain health. Discover our progress by viewing our pipeline: https://lnkd.in/gWZG5wsj
-
-
Join our team! MapLight Therapeutics, Inc. is hiring for several key roles across various departments. Explore career opportunities with us and join a company dedicated to advancing treatments for neurological disorders. Apply today. https://lnkd.in/dgHz9Mrx
-
We are proud to partner with organizations like the Autism Science Foundation. Together, we are working to advance research with the aim of improving care and treatment outcomes for those with Autism Spectrum Disorder. Learn more by visiting our website. https://lnkd.in/gxwYtiwy
-
Are you familiar with our IRIS Clinical Trial? It's an important step in our work with Autism Spectrum Disorder (ASD). At MapLight Therapeutics, we are committed to advancing research and developing innovative treatments for ASD. Learn more about the IRIS Trial and our dedication to making a difference with potential new treatments for this community. https://lnkd.in/e9YaUN6H
-